Dr. Hsieh serves as Special Medical Advisor for Anbogen Therapeutics, where he is responsible for overseeing the Company’s global clinical development portfolio since 2020. Dr. Hsieh is also the Chief Medical Officer for IMPACT Therapeutics in Shanghai. In the recent 3 years, he was instrumental in the clinical development strategy of the company’s innovative assets, establishing fully functional clinical research team, and advancing IMPACT’s compounds to build one of the most comprehensive clinical stage portfolio in synthetic lethality area globally. Under his leadership, IMPACT successfully obtain US FDA IND approval in four clinical trials with innovative study designs, including two first-in-human study with Wee1 inhibitor, and ATR inhibitors.Prior to joining Anbogen, Dr. Hsieh served as the Chief Medical Officer of ASLAN Pharmaceuticals, where he led a the clinical development team to successfully initiated 9 clinical trials, including 5 multinational trials (1 pivotal trial) and 4 single-country trials, ranging from phase 1 to global pivotal studies. Dr. Hsieh held a Medical Advisor position at Novartis Oncology, was responsible for clinical studies of hematology pipeline, including both global and regional studies. Dr. Hsieh obtained his M.D. from National Yang-Ming University, Taiwan, and is board certified in internal medicine, hematology, oncology, and blood and marrow transplantation. He also is a active member of Taiwan Taiwan Oncology Society, ASCO, ESMO and CSCO.